# Olopatadine 0.2% for the Treatment of Allergic Conjunctivitis

> **NCT00331500** · PHASE3 · COMPLETED · sponsor: **Alcon Research** · enrollment: 287 (actual)

## Conditions studied

- Allergic Conjunctivitis

## Interventions

- **DRUG:** Olopatadine Hydrochloride Ophthalmic Solution, 0.2%
- **DRUG:** Olopatadine Hydrochloride Ophthalmic Solution Vehicle

## Key facts

- **NCT ID:** NCT00331500
- **Lead sponsor:** Alcon Research
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-04-18
- **Primary completion:** 2006-07-27
- **Final completion:** 2006-07-27
- **Target enrollment:** 287 (ACTUAL)
- **Last updated:** 2017-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00331500

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00331500, "Olopatadine 0.2% for the Treatment of Allergic Conjunctivitis". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00331500. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*